1. Prolymphocytic leukaemia of B- and T-cell subtype: a state-of-the-art paper.
- Author
-
Dungarwalla, M., Matutes, E., and Dearden, C. E.
- Subjects
- *
LYMPHOCYTIC leukemia , *T cells , *B cells , *IMMUNOPHENOTYPING , *HUMAN cytogenetics , *CYTOLOGY , *PROGNOSIS - Abstract
Prolymphocytic leukaemias of B and T cell subtype are rare diseases. Despite recent advances in immunophenotyping and molecular cytogenetics, leading to a better understanding of the underlying cell biology of the prolymphocytic leukaemias, prognosis for these patients remains poor. Purine analogues and monoclonal antibodies have shown efficacy in B-cell prolymphocytic leukaemia although further studies are warranted. Monoclonal antibody therapy with alemtuzumab has significantly improved outcome in T-cell prolymphocytic leukaemia (T-PLL) but responses are still transient and further disease progression is inevitable. While allogeneic stem cell transplant is an attractive option, due to the older age group of T-PLL patients the morbidity and mortality associated with the procedure is significant. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF